|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hulka BS and Moorman PG: Breast cancer:
Hormones and other risk factors. Maturitas. 38:103–113; discussion
113–116. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baan R, Straif K, Grosse Y, Secretan B, El
Ghissassi F, Bouvard V, Altieri A and Cogliano V: WHO International
Agency for Research on Cancer Monograph Working Group:
Carcinogenicity of alcoholic beverages. Lancet Oncol. 8:292–293.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Key J, Hodgson S, Omar RZ, Jensen TK,
Thompson SG, Boobis AR, Davies DS and Elliott P: Meta-analysis of
studies of alcohol and breast cancer with consideration of the
methodological issues. Cancer Causes Control. 17:759–770. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bertucci F, Finetti P and Birnbaum D:
Basal breast cancer: A complex and deadly molecular subtype. Curr
Mol Med. 12:96–110. 2012. View Article : Google Scholar :
|
|
6
|
Lumachi F, Brunello A, Maruzzo M, Basso U
and Basso SM: Treatment of estrogen receptor-positive breast
cancer. Curr Med Chem. 20:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arvold ND, Taghian AG, Niemierko A, Abi
Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL and
Harris JR: Age, breast cancer subtype approximation, and local
recurrence after breast-conserving therapy. J Clin Oncol.
29:3885–3891. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Potemski P, Kusinska R, Watala C,
Pluciennik E, Bednarek AK and Kordek R: Prognostic relevance of
basal cytokeratin expression in operable breast cancer. Oncology.
69:478–485. 2005. View Article : Google Scholar
|
|
10
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lund MJ, Butler EN, Hair BY, Ward KC,
Andrews JH, Oprea-Ilies G, Bayakly AR, O'Regan RM, Vertino PM and
Eley JW: Age/race differences in HER2 testing and in incidence
rates for breast cancer triple subtypes: A population-based study
and first report. Cancer. 116:2549–2559. 2010.PubMed/NCBI
|
|
12
|
Mayer IA: Treatment of HER2-positive
metastatic breast cancer following initial progression. Clin Breast
Cancer. 9(Suppl 2): S50–S57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murphy CG and Fornier M: HER2-positive
breast cancer: Beyond trastuzumab. Oncology (Williston Park).
24:410–415. 2010.
|
|
17
|
Zhou Z and Hick DG: HER2 Amplification or
Overexpression in Upper GI Tract and Breast Cancer with Clinical
Diagnosis and Treatment. Siregar Y: INTECH Open Access Publisher;
2013
|
|
18
|
Xing X, Wang SC, Xia W, Zou Y, Shao R,
Kwong KY, Yu Z, Zhang S, Miller S, Huang L, et al: The Ets protein
PEA3 suppresses HER-2/neu overexpression and inhibits
tumorigenesis. Nat Med. 6:189–195. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Furth PA: STAT signaling in different
breast cancer sub-types. Mol Cell Endocrinol. 382:612–615. 2014.
View Article : Google Scholar
|
|
20
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duru N, Fan M, Candas D, Menaa C, Liu HC,
Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, et al:
HER2-associated radioresistance of breast cancer stem cells
isolated from HER2-negative breast cancer cells. Clin Cancer Res.
18:6634–6647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
William EJ: MSM reviewed. J Equine Vet
Sci. 7:1987.
|
|
23
|
Silva Ferreira AC, Rodrigues P, Hogg T and
Guedes De Pinho P: Influence of some technological parameters on
the formation of dimethyl sulfide, 2-mercaptoethanol, methionol,
and dimethyl sulfone in port wines. J Agric Food Chem. 51:727–732.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rose SE, Chalk JB, Galloway GJ and
Doddrell DM: Detection of dimethyl sulfone in the human brain by in
vivo proton magnetic resonance spectroscopy. Magn Reson Imaging.
18:95–98. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Caron JM, Bannon M, Rosshirt L, Luis J,
Monteagudo L, Caron JM and Sternstein GM: Methyl sulfone induces
loss of metastatic properties and reemergence of normal phenotypes
in a metastatic cloudman S-91 (M3) murine melanoma cell line. PLoS
One. 5:e117882010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barrager E, Veltmann JR Jr, Schauss AG and
Schiller RN: A multicentered, open-label trial on the safety and
efficacy of methylsulfonylmethane in the treatment of seasonal
allergic rhinitis. J Altern Complement Med. 8:167–173. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim LS, Axelrod LJ, Howard P, Buratovich N
and Waters RF: Efficacy of methylsulfonylmethane (MSM) in
osteoarthritis pain of the knee: A pilot clinical trial.
Osteoarthritis Cartilage. 14:286–294. 2006. View Article : Google Scholar
|
|
28
|
Joung YH, Lim EJ, Darvin P, Chung SC, Jang
JW, Do Park K, Lee HK, Kim HS, Park T and Yang YM: MSM enhances GH
signaling via the Jak2/STAT5b pathway in osteoblast-like cells and
osteoblast differentiation through the activation of STAT5b in
MSCs. PLoS One. 7:e474772012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lim EJ, Hong DY, Park JH, Joung YH, Darvin
P, Kim SY, Na YM, Hwang TS, Ye SK, Moon ES, et al:
Methylsulfonylmethane suppresses breast cancer growth by
down-regulating STAT3 and STAT5b pathways. PLoS One. 7:e333612012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim JH, Shin HJ, Ha HL, Park YH, Kwon TH,
Jung MR, Moon HB, Cho ES, Son HY and Yu DY: Methylsulfonylmethane
suppresses hepatic tumor development through activation of
apoptosis. World J Hepatol. 6:98–106. 2014.PubMed/NCBI
|
|
31
|
Ross JS: Update on HER2 testing for breast
and upper gastrointestinal tract cancers. Biomarkers Med.
5:307–318. 2011. View Article : Google Scholar
|
|
32
|
Winstanley J, Cooke T, Murray GD,
Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A,
Barraclough BR and Rudland PS: The long term prognostic
significance of c-erbB-2 in primary breast cancer. Br J Cancer.
63:447–450. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hicks DG, Yoder BJ, Short S, Tarr S,
Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, et
al: Loss of breast cancer metastasis suppressor 1 protein
expression predicts reduced disease-free survival in subsets of
breast cancer patients. Clin Cancer Res. 12:6702–6708. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Emde A, Köstler WJ and Yarden Y:
Association of Radiotherapy and Oncology of the Mediterranean arEa
(AROME): Therapeutic strategies and mechanisms of tumorigenesis of
HER2-over-expressing breast cancer. Crit Rev Oncol Hematol.
84(Suppl 1): e49–e57. 2012. View Article : Google Scholar
|
|
36
|
Chung SS, Giehl N, Wu Y and Vadgama JV:
STAT3 activation in HER2-overexpressing breast cancer promotes
epithelial-mesenchymal transition and cancer stem cell traits. Int
J Oncol. 44:403–411. 2014.
|
|
37
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et
al: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and
AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.
|
|
38
|
Joung YH, Lim EJ, Lee MY, Park JH, Ye SK,
Park EU, Kim SY, Zhang Z, Lee KJ, Park DK, et al: Hypoxia activates
the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer
cells. Exp Mol Med. 37:353–364. 2005. View Article : Google Scholar : PubMed/NCBI
|
